medigraphic.com

1999, Number 3

<< Back Next >>

Enf Infec Microbiol 1999; 19 (3)

Enterobacteriaceae with extended spectrum betalactamases: their importance as nosocomial pathogen agents

Morfín OR, Rodríguez NE

Language: Spanish
References: 101
Page: 116-132
PDF size: 107.70 Kb.


ABSTRACT

This article reviews the emergence evolution, epidemiology, laboratory detection and options for therapy and control of bacteria capable of producing extended spectrum betalactamases (ESBL). ESBL producing bacteria is now commonly found in nosocomial isolates like Klebsiella pneumoniae. ESBL mediated resistance first appeared in Europe in 1983, soon after oxymino-cephalosporins were introduced, and then spread to the America in 1988. ESBL bacteria are acquired by hospitalized patients that have risk factors that include duration of stay, invasive procedures and previous antibiotic exposure. Nosocomial infections caused by ESBL producing bacteria increase the morbidity, mortality and costs of the hospitalized patients. The therapeutic options are limited and complicated by the production of other mechanisms of resistance to the antibiotics of choice for the treatment of nosocomial isolates resistant to third-generation cephalosporins.


REFERENCES

  1. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for ß-lactamases and its correlations with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.

  2. Fleming PC, Goldner M, Glass DG. Observations on the nature, distribution and significance of cephalosporinase. Lancet 1963;1:1399-401.

  3. Richmond MH, Sykes RB. The ß-lactamases of Gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973;9:31-88.

  4. Sykes RB, Matthew M. The ß-lactamases of Gram-negative bacteria and their role in resistance to ß-lactam antibiotics. J Antimicrob Chemother 1976;2:115-57.

  5. Mitsuhashi Sl, Inove M. Mechanisms of resistance to Beta- Lactam antibiotics. Beta-Lactam antibiotics. New York: Springer- Verlag, 1981:41-56.

  6. Ambler RP. A standard numbering scheme for the Class A ßlactamases. Biochem J 1991;276:269-72.

  7. Jaurin B, Grundstrom T. ampC Cephalosporinase of Escherichiacoli K-12 has a different evolutionary origin from that of betalactamases of the penicillinase type. Proct Natl Acad Sci USA 1981;78:4897-901.

  8. Huovinen P, Jacoby GA. Secuence of the PSE-1 ß-lactamase gene. Antimicrob Agents Chemother 1991;35:2428-30.

  9. Ouellette M, Bissonnette L, Roy PH. Precise insertion of antibiotic resistant determinants into Tn21-Like transposons: Nucleotide sequence of the OXA-1 ß-lactamase. Proc Nat Acad Sci USA 1987;84:7378-82.

  10. Bush K. ß-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1988;1:109-23.

  11. Bush K. Classification of ß-lactamases: Groups 1, 2a, 2b, and 2b’. Antimicrob Agent Chemother 1989;33:264-70.

  12. Bush K. Characterization of ß-lactamases. Antimicrob Agent Chemother 1989;33:259-63.

  13. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940;146:837.

  14. Rammelkamp CH, Maxon T. Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med 1942;51:386-9.

  15. Kirby WMM. Extraction of a highly potent penicillin inactivator from penicillin-resistant staphylococci. Science 1944;99:452- 3.

  16. Barber M, Whitehead JEM. Bacteriophage types in penicillinresistant staphylococcal infection. Br Med J 1949;2:565-56.

  17. Datta N, Ktomichalou P. Penicillinase resistance cotransferance by infectious R-factors in enterobacteriaceae. Nature 1968;208:239-41.

  18. Medeiros A. Evolution and dissemination of ß-lactamases accelerated by generations of ß-lactam antibiotics. Clin Infect Dis 1997;24:S19.

  19. Fournier B, Lu CY, LaGrange PH, Krishnamoorthy R, Philippon A. Point mutation in the pribnow box, the molecular basis of ßlactamase overproduction in Klebsiella oxytoca. Antimicrob Agents Chemother 1995;39:1365-8.

  20. Sanders CC, Sanders WEJ. Emergence of resistance to cefamandole: Possible role of cefoxitin-inducible Beta- Lactamases. Antimicrob Agents Chemother 1979;15:792-7.

  21. Sanders CC, Sanders WEJ. Type I ß-lactamases of Gramnegative bacteria: Interaction with beta-lactam antibiotics. J Infect Dis 1986;154:792-800.

  22. Vu H, Nikaido H. Role of ß-lactam hydrolysis in the mechanism of resistance of a ß-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum ß-Lactams. Antimicrob Agents Chemother 1985;27:393-8.

  23. Yang Y, Livermore DM. Chromosomal ß-lactamase expression and resistance to ß-lactam antibiotics in Proteus vulgaris and Morganella morganii. Antimcirob Agents Chemother 1988;32:1385-91.

  24. Raimondi A, Traverso A, Nikaido H. Imipenem and meropenemresistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Antimicrob Agents Chemother 1991;35:1174-80.

  25. Bush K, Tanaka SK, Bonner DP, Sykes RB. Resistance caused by decreased penetration of ß-lactam antibiotics into Enterobacter cloacae. Antimicrob Agents Chemother 1985;27:555-60.

  26. Knothe H, Shah P, Kromery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae, and Serratia marcescens. Infection 1983;11:315-7.

  27. Brun-Buisson C, Legrand P, Philippon A, Montravers F, AnsquerM, Duval J. Transferable enzymatic resistance to thirdgeneration cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987;II:302-3.

  28. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille- Michaud A, Perroux R, Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: Identification of CTX-1 a novel ß-lactamase. J Antimicrob Chemother 1987;20:323-34.

  29. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jacoby GA. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.

  30. Urban C, Meyer KS, Mariano N. Identification of TEM-26 ßlactamase responsible for a major outbreak of ceftazidimeresistant Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:392.

  31. Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM. Outbreak of ceftazidime resistance due to a novel extended-spectrum ß-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991-6.

  32. Yang YPW, Livermore DM. Biochemical characterization of a ß-Lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother1990;34:755-8.

  33. Nass T, Vandel L, Sougakoff W, Livermore DM, Nordmann P.Cloning and sequence analysis of the gene for a carbapenemhydrolyzing class A ß-lactamase, Sme-1 from Serratia marcescens S6. Antimicrob Agents Chemother 1994;38:1262- 70.

  34. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmidmediated ß-lactamase (MIR-1) conferring resistance to oxyimino-and o-methoxy ß-lactams in clinical isolates of Klebsiella penumoniae. Antimicrob Agents Chemother 1990;34:2200-9.

  35. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;35:147-51.

  36. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrob Agents Chemother 1985;28:302-7.

  37. Philippon A, Paul G, Vedel G, Nevot P. Resistance plasmidique aux cephalosporines de 3 generation. Presse Med 1987;17:1883-9.

  38. Petit A, Sirot D, Chanal C, Sirot J, Labia R, Gerbaud G, Cluzel R. Novel plasmid-mediated ß-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins. Antimicrob Agents Chemother 1988;32:626-30.

  39. Chanal CM, Sirot DL, Labia R, Petit A, Morand A, Sirot JL, Cluzel RA. Comparative study of a novel plasmid-mediated betalactamase, CAZ-2, and the CTX-1 enzymes conferring resistance to broad spectrum cephalosporins. Antimicrob Agents Chemother 1988;32:1660-5.

  40. Bure A, Legrand P, Arlet G, Jarlier V, Paul G, Philippon A. Dissemination in five french hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam. Eur J Clin Microbiol Infect Dis 1988;7:780-2.

  41. Gutmann L, Kitzis MD, Klein B, Goldstein F, Nhieu VT, Carlet J, Williamson R. Plasmid-mediated ß-Lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Rev Infect Dis 1988;10:860-6.

  42. Labia R, Morand A, Tiwari K, Sirot J, Sirot D, Petit A. Interactions of new plasmid-mediated ß-lactamases with third-generation cephalosporins. Rev Infect Dis 1988;10:885-91.

  43. Bauernfeind A, Horl G. Novel R-factor from ß-lactamase of Escherichia coli confering resistance to cephalosporins. Infection 1987;15:257-9.

  44. Spencer RC, Wheat PF, Winstanley TG, Cox DM, Pleasted SJ. Novel ß-lactamase in a clinical isolate of Klebsiella pneumoniae confering unusual resistance to ß-lactam antibiotics. J Antimicrob Chemother 1987;20:919-21.

  45. Roy C, Segura M, Tirado M, Reig R, Hermida M, Teruel D, Foz A. Frequency of plasmid-determined Beta-lactamases in 680 consecutively isolated strains of Enterobacteriaceae. Eur J Clin Microbiol 1985;4:146-7.

  46. Philippon A, Labia R, Jacoby G. Extended-spectrum ßlactamases. Antimicrob Agents Chemother 1989;33:1131-6.

  47. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type ß-lactamase: Mutations, specificity and three-dimensional structure. Antimicrob Agents Chemother 1995;39:2593-601.

  48. Jacoby GA. Editorial response: Epidemiology of extendedspectrum ß-lactamases. Clin Infect Dis 1998;27:81-83.

  49. Jacoby GA, Han P. Detection of extended-spectrum ßlactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microb 1996;34:908-11.

  50. Sirot DL, Goldstein FW, Soussy CJ, et al. Resistance to cefotaxime and seven other ß-lactams in members of the family Enterobacteriaceae: A 3-year survey in France. Antimcirob Agents Chemother 1992;36:1677-87.

  51. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistant among selected nosocomial gram-negative bacteria in the United States. J Infect Dis 1994;170:1622-5.

  52. Monnet DL, Biddle JW, Edwards JR, et al. Evidence of interhospital transmission of extended-spectrum ß-lactamresistant Klebsiella pneumoniae in the United States, 1986 to 1993. Infect Control Hosp Epidemiol 1997;18:492-8.

  53. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 1995;9:497-530.

  54. Courvalin P. Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1994;38:1447-51.

  55. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-81.

  56. Lucet JC, Chevret S, Decre D, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: Epidemiology and risk factors for acquisition. Clin Infect Dis 1996;22:430-6.

  57. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-Resistant Klebsiella pneumoniae, and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation. J Infect Dis 1996;174:529-36.

  58. Peña C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum ß-lactamases. Antimicrob Agents Chemother 1998;42:53-58.

  59. De Champs C, Rouby D, Sirot D, Beytout D, Gourgand JM. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) betalactamase. J Hosp Infect 1991;18:5-13.

  60. Hibberdd PL, Jacoby GA. Multiply drug resistant Klebsiella pneumoniae strains: Predictors of acquisition and mortality. [abstract C46] In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents Chemotherapy. Washington D.C. American Society for Microbiology,1894:87, 1994:87.

  61. Swanson H, Schulte EE, Venezia RA, Kacika MA. Risk factor assessment of neonates colonized or infected with an extended spectrum ß-lactamase producing Klebsiella oxytoca in a neonatal intensive care unit. [abstract J26] In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents Chemotherapy. Washington D.C. American Society for Microbiology,1896:223, 1996:223.

  62. Paterson DL, Ko WC, Mohapatra S, Van Gottberg A, Mulazimoglu L, Casellas JM, et al. Klebsiella pneumoniae bacteremia: Impact of extended spectrum beta-lactamase production in a study of 216 patients. [abstract J210] In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents Chemotherapy. Washington D.C. American Society for Microbiology,1897:328, 1997:328.

  63. Morfín OR, Bonilla C, Esparza AS, Heredia CJ, Atilano DG, Rodríguez CJJ, et al. Risk factors from extended spectrum beta-lactamases in Klebsiella pneumoniae, Klebsiella oxytoca, and E. coli. [abstract L20] In: Program and abstracts of the 98th American Society for Microbiology 1998.

  64. Peña C, Pujol M, Ricart A, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum ßlactamase (ESBL-KP) in the intensive care unit. J Hospital Infection 1997;35:9-16.

  65. Piroth L, Aubé H, Doise JM, Martin VM. Spread of extendedspectrum ß-lactamase-producing Klebsiella pneumoniae: Are ß-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998;27:76-80.

  66. Smith EG, Tillman SB, Howell WA, Longfield NR, Jorgensen HJ. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended- spectrum ß-lactamase. Antimicrob Agents Chemother 1990;34-6:1290-3.

  67. Medeiros AA. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum Beta-lactamases have arrived in North America. Ann Intern Med 1993;119:428-30.

  68. Jacoby GA, Medeiros AA. More extended-spectrum ßlactamases. Antimicrob Agents Chemother 1991;35:1697-704.

  69. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.

  70. De Champs C, Sauvant MP, Chanal C, et al. Prospective survey of colonization and infection caused by expanded spectrum-ß-lactamases producing members of the family Enterobacteriaceae in an intensive care unit. J Clin Microbiol 1989;27:2887-90.

  71. Bingen EH, Desjardins P, Arlet G, et al. Molecular epidemiology of plasmid spread among extended broad-spectrum ßlactamase- producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin Microb 1993;31:179-84.

  72. Nouvellon M, Pons JL, Sirot D, Combe ML, Lemeland JF. Clonal outbreaks of extended-spectrum ß-lactamase-producing strains of Klebsiella pneumoniae demonstrated by antibiotic susceptibility testing, ß-lactamase typing, and multilocus enzyme electrophoresis. J Clin Microbiol 1994;32:2625-7.

  73. Arlet G, Rouveau M, Casin I, Bouvet PJM, Lagrange PH, Philippon A. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 ß-lactamase and which were isolated in 14 french hospitals. J Clin Microbiol 1994;32:2553-8.

  74. Venezia RA, Scarano FJ, Preston KE, Steele LM, Root TP, Limberger R, et al. Molecular epidemiology of an SHV-5 extended- spectrum ß-lactamase in Enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin Infect Dis 1995;21:915-23.

  75. French GL, Shannon KP, Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad spectrum cephalosporins and ß-lactam-ß-lactamase inhibitor combinations by hyperproduction of SHV-5 ß-lactamase. J Clin Microbiol 1996;34:358-63.

  76. Neuwrith C, Siebor E, López J, Pechinot A, Karzmierczak A. Outbreak of TEM-24 producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum ß-lactamase to other members of the family of the Enterobacteriaceae. J Clin Microbiol 1996;34:76-79.

  77. Gaillot O, Maruejouls C, Abachin E, Lecuru F, Arlet G, Simonet M, Berche P. Nosocomial outbreak of Klebsiella pneumoniae producing SHV-5 extended-spectrum ß-lactamase, originating from a contaminated ultrasonography coupling gel. J Clin Microbiol 1998;36:1357-60.

  78. Jacoby GA, Medeiros AA, O Brien TF, Pinto ME, Jiang H. Broad-spectrum, transmissible ß-lactamases. N Engl J Med 1988;319:723.

  79. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) confering selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989;33:1451-6.

  80. Weber DA, Sanders CC, Bakken JS, Quinnm JP. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli. J Infect Dis 1990;162:460-5.

  81. Jarlier V, Nicilas MH, Fournier G, Philippon A. Extended broadspectrum ß-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.

  82. Thomson SK, Sanders CC. Detection of extended-spectrum ßlactamases in members of the family Enterobacteriacea. Comparison of the Double-Disk and Three-Dimensional Test. Antimicrob Agents Chemother 1992;36:1877-82.

  83. Bush K. Is it important to identify extended-spectrum betalactamse- producing isolates? Eur J Clin Microbiol Infect Dis 1996;15:361-4.

  84. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.

  85. Matthew M, Harris AM, Marshall MJ, Ross GW. The use of analytical isoelectric focusing for detection and identification of ß-lactamases. J Gen Microbiol 1975;88:169-78.

  86. Nüesch-Inderbinen MT, Hächler H, Kayser FH. Detection of extended-spectrum SHV ß-lactamases in clinical isolates by a precise molecular genetic method and comparison with the E test ESBL. Eur J Clin Microb Infect Dis 1996;15:398-402.

  87. Sanders CC. ß-lactamases of gram-negative bacteria: New challenges for new drugs. Clin Infect Dis 1992;14:1089-99.

  88. Rice LB, Eckstein EC, DeVente J. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118.

  89. Thauvin EC, Marie FT, Moellering RC, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum ß-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997;41:1053-7.

  90. Fantin B, Pangon B, Potel G, et al. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like ßlactamase. Antimicrob Agents Chemother 1990;34:581-6.

  91. Caron F, Gutmann L, Bure A, et al. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 ßlactamase. Antimicrob Agents Chemother 1990;34:2070-4.

  92. Fournier JL, Ramisse F, Jacolot AC, et al. Assessment of two penicillins plus ß-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections. Antimicrob Agents Chemother 1996;40:325-30.

  93. Rice LB, Carias LL, Bonomo RA. Molecular genetics of resistance to both ceftazidime and ß-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to ßlactam therapy. J Infect Dis 1996;173:151-8.

  94. Leleu G, Kitzis MD, Vallois JM, Gutmann L, Decazes JM. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum ßlactamase. Antimicrob Agents Chemother 1994;38:195-8.

  95. Jacoby GA, Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990;34:858- 62.

  96. Bradford PA, Urban C, Jaiswal A, Mariano N. SHV-7, a novel cefotaxime-hydrolyzing ß-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 1995;39:899-905.

  97. Rice LB, Carias LL, Shlaes DM. In vivo efficacies of ß-lactam ß-lactamase inhibitor combinations against a TEM-26 producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1994;38:2663-4.

  98. Rice LB, Yao JDC, Klimm K, Eliopoulos GM, Moellering RC. Efficacy of different ß-lactams against an extended-spectrum ß-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother 1991;35:1243-4.

  99. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF. Susceptibility of ESBL-producing organisms. Antimicrob Agents Chemother 1995;39:1187-90.

  100. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weihsten RA. Multiple antibiotic-resistance Klebsiella, and Escherichia coli in nursing homes. JAMA 1999;281:517.

  101. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233.




2020     |     www.medigraphic.com